CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 35 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Placebo 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05314374
NCT05314374Phase 1Completed
CompareCT.gov

Effect of Ileocolic-released Conjugated Bile Acid on Satiety, Entero-Endocrine Cell Function, and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype

Mayo Clinic·interventional·Posted Apr 6, 2022·Updated May 4, 2025

In Brief

A Phase 1 clinical trial evaluating Ileocolonic-release conjugated bile acid and Placebo for Obesity and Healthy. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this research is to study the effect of the study drug (a conjugated bile acid dietary supplement) or placebo on cell function, hormones and body weight.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Healthy
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedApr 6, 2022
Enrollment StartMay 12, 2023
Primary CompletionMar 22, 2024
Study CompletionNov 13, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.2 years ago

Interventions

Ileocolonic-release conjugated bile aciddietary

500 mg tablets orally twice daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 5 days. Subjects will receive 500 mg twice daily during their first week and 1000 mg twice daily for the rest of the study.

Placebodrug

Placebo looks exactly like the study drug, but it contains no active ingredient. 500 mg tablets orally twice daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 5 days. Subjects will receive 500 mg twice daily during their first week and 1000 mg twice daily for the rest of the study.